Oncology
Relapsed/Refractory Multiple Myeloma
Expert Roundtables Podcast: Salvage Therapy After BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
The rapidly expanding treatment landscape for relapsed/refractory multiple myeloma has created new opportunities and challenges for managing relapse after BCMA-directed CAR T-cell therapy. As noted by our experts in today’s podcast, selecting the most appropriate salvage therapy depends on several factors, including prior BCMA-directed treatment as well as disease and patient characteristics.
Costa LJ, Banerjee R, Mian H, et al. International Myeloma Working Group Immunotherapy Committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39(3):543-554. doi:10.1038/s41375-024-02482-6
Dima D, Banerjee R, Hansen DK. CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma. Hematology Am Soc Hematol Educ Program. 2025;2025(1):324-333. doi:10.1182/hematology.2025000721
Martino EA, Vigna E, Bruzzese A, et al. Selinexor in multiple myeloma. Expert Opin Pharmacother. 2024;25(4):421-434. doi:10.1080/14656566.2024.2333376
Min C, Zhong X, Cui Y, Zhang H, Wang Q. Strategies for salvage therapy post CAR-T therapy failure in refractory/relapsed multiple myeloma patients. Front Pharmacol. 2025;16:1515555. doi:10.3389/fphar.2025.1515555
Wang S, Li W, Li J, Guo Z, Chen J, Hu Z. Antigen escape in CAR-T therapy: a tumor microenvironment perspective from hematological to solid tumors. Int J Cancer. 2026;158(4):835-846. doi:10.1002/ijc.70117
Explore More in Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Treatment Beyond the Clinical Trial Setting for Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
